Wayne, Pa., Feb. 27, 2025 (Globe Newswire) – Tempian Incorporated (NYSE: TFX), A Leading Global Provider of Medical Technologies, Today Announced Inta A Definitive to Acques substantially all of the vascular intervention of Biotronik se & Co. KG for an estimated cash payments on closing of approximately € 760 million, tex Certain adjustments as provided in the purchasent including some non -transfer capital and other customary adjustments. The purchase is subject to customary closure conditions, including obtaining certain regulatory approval, and is expected to be completed by the end of the third quarter of 2025.
Purchase reflects Teblex’s commitment to invest in estimated $ 10 billion intervening cardiology and peripheral vascular market served by Post Close’s portfolio.12 The acquired business will expand the TONEX intervention portfolio to include a wide suite of vascular intervention equipment, such as drug-coated balloons, drug stents, covered stents, balloons and self-extension of bare metal stents and balloon catheters. In 2023, approximately 75% of the earnings earned were generated by coronary interventions while the remainder approximately 25% were accompanied by peripheral intervention procedures.3
“We are excited to announce the purchase of the business of vascular intervention of biotronic, which we anticipate will significantly improve our global presence in Cath Lab, expand our group of innovative technologies and improve patient care,” said Liam Kelly, President and Chief Executive Officer. “We believe that buying will allow us to position this advanced coronary portfolio along with our existing intervention business and create our global trace in the fast -growing suburban intervention market. In particular, obtained coronary products will be highly complement Inheritance and offers by combining existing television products with vascular intervention therapeutic equipment. Resorbing.3and provide additional degrees for investment in innovation. “
The acquired vascular intervention business consists of a comprehensive and differentiated portfolio for coronary and peripheral interference carried out in the Cath Laboratory and the intervention of radiology. In vascular coronary interventions, the main products include the panthera luxurious panthera drug catheter, the Novel PK Papyrus ™ Coronary Coronary for acute coronary artery perforations, and stent eluting of the ORSIRO Drugs, an ultrathine stent, For peripheral interventions, the portfolio includes PASSEO ™ -18 LUX LUX Cateter Ballobe Catheter Loined with Drugs, Dynecik ™ -35 -Tullumbace -Expandable with Cobalt Chromium Stent, and Sentar ™ -18 Self -Explained 4F.
Purchase of vascular intervention business will also allow Teblex the opportunity to invest and expand the clinical trial program for Biotronik ™, a resorbable resorbable resorbable (RMS) metal technology, including possible tracking of the US market. Freesolve ™, who received its CE sign in February 2024, is indicated in CE-Mark accepting places for lesions of the coronary arteries de Novo. The combination of temporary scaffolding with drug distribution is projected to address the current trend of coronary and endovascular intervention procedures towards leaving less permanent equipment. As shown in the Biomag study, the freeness ™ RMS demonstrated resorption after 12 months, a degree of intended failure comparable to contemporary drug stents, and no defined or possible scaffolding thrombosis.4,5 The main European Biomag study is now being recorded.
Education established by Tempian colleagues, the extension of patients and the clinical platform for its existing intervention business will be further used by the acquired portfolio of coronary and peripheral vascular intervention equipment.
While intervening cardiology and peripheral intervention markets increase on a global basis, Teblex predicts that this purchase will improve its offers for cardiac and suburban care specialists, while significantly advancing its corporate growth objectives.
Financial effort of purchasing vascular intervention
Acquired biotronic products maintained a continuous coin revenue from 5.4% from 2022 to 2024. The products earned are expected to generate approximately € 91 million in revenue in the fourth quarter of 2025. Starting in 2026, biotronic purchase is expected to provide continuous increase in revenue by 6% or better.
Excluding non -repeated purchasing accounting items and other costs related to purchase and integration, the transaction is expected to be approximately $ 0.10 accressive for the company’s regulated revenue for the first year of ownership from the closing date, and is increasingly accressive, after that.
Teblex plans to first finance the purchase through a new loan and rotating borrowings under its existing credit facility and cash in hand.
Moreover, the company entered into derivative foreign exchange contracts to protect economically against the exposure of the foreign currency associated with the consideration of the money needed to complete the purchase.
Company to wait for the Conference Call
The company will organize a conference call to discuss its fourth quarter financial results and provide an operational update including transaction at 8:00 AM et Thursday, February 27, 2025. To participate in the Conference Call, please use this link to register pre-registered and obtain call information. Call can also be achieved through a direct audio webcast on the company’s website, Teblex.com.
A call audio reproduction will be available starting at 11:00 am, February 27, 2025, whether on the telephone website or by phone. The call can be reached by calling 1 800 770 2030 (SH.BA and Canada) or 1 609 800 9909 (all other countries). The Conference ID is 69028.
About Tempian Incorporated
As a global medical technology provider, Tebslex is driven by our goal to improve the health and quality of life of people. Through our vision of becoming the most reliable partner in health care, we offer a diverse portfolio with solutions in the areas of anesthesia therapy, urgent medicine, intervention and radiology, surgery, vascular access and urology. We believe that the potential of great people, the intention -driven innovation and world -class products can form the future direction of healthcare.
Tempian is the home of Arrow ™, Barigel ™, Deknatel ™, LMA ™, Pilling ™, Quikclot ™, Rüsch ™, Urolift ™ and Weck ™ – Trusted brands united by a common sense of purpose.
At Teblex, we are strengthening the future of health care. For more information, visit telex.com.
Not all products can be available in all countries. Over-reference equipment coated with medication are not available in the United States and Japan.
References:
- Idata research. (2023). Global market ratio suit for peripheral vascular equipment: with the impact of Covid-19 (IDATA_GLPV24_MS).
- Idata research. (2023). Global Market Report Suite for Infective Cardiology Equipment: With Covid-19 Impact (Idua_glic23_ms).
- Based on Biotronic 2023 net income current in continuous currency.
- Seguchi M, Aytekin A, Pocket E, Haude M, Wlodarczak A, Van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, TEELG M, OliveCrona G, Vermeersch P, Waksman. M. Vascular response after implantation of the coronary magnesium scaffolding of third generation drug re-enlogging: an intravascular analysis of the first-inhuman biomag study image. Eurointervention. 2024 is 16; 20 (18): E1173-E1183. DOI: 10.4244/EIJ-D-24-00055. PMID: 39279514; PMCID: PMC11384225. The study was sponsored by biotronic. M. Seguchi, M. Haude, JF Iglesias, J. Bennett, GG Toth, M. Wiemer, G. Olivecrona, R. Waksman, Hm Garcia-Gare and M. Joner are paid biotronic consultants.
- Haude M, Wlodarczak A, Van der Schaaf RJ, Torzewski J, Ferdinande B, Escned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Gargia HM, Waksman R. A New Sc, Coronary lesions (dreams 3): one-year results of the first-inhuman study biomag. Eurointervention. 2023 7 August; 19 (5): E414-E422. DOI: 10.4244/EIJ-D-23-00326. PMID: 37334655; PMCID: PMC10397670.
Future statements
This press release contains future statements, including, but not limited to, statements regarding our proposed acquisition of vascular intervention business, commercialized products and the pipeline of our vascular intervention, and vascular intervention of business intervention and projected business foreseen, including, in any case. provided and foreseen in the foreseen timely proposal time. Current results may differ materially from those in future statements due to, among other things, the possibility that the purchase will not close; The unexpected costs and the duration of the time required to meet the legal requirements and regulatory approval applicable to the transaction; unforeseen difficulties and expenses regarding integration programs; client and shareholder reaction to the transaction; risks associated with transaction financing; transaction disruption making it more difficult to maintain business relationships and operations; significant transaction costs; Unknown obligations; Risk of regulatory actions regarding the proposed purchase; changes in general and international economic conditions, including fluctuations in foreign currency exchange rates; and other factors described or involved in our records of the Insurance and Exchange Commission, including our annual report for the 10-K form for the year ended on December 31, 2023.
Caution: Federal law (sh.ba) limits these equipment for sale or use with or with a doctor’s order.
Tempian, Telex Logo, Arrow, Barigel, Deknatel, LMA, Pilling, Quikclot, Titan SGS, Rüsch, Urolift and Weck are trademarks or registered brands of Tempian Incorporated or his associates in the US and/or other places. Other names are trademarks of their respective owners. Refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions. Information in this document is not a substitute for product guidelines for use. Not all products can be available in all countries. Please contact your local representative.
© 2025 Teblex Incorporated. All rights reserved.
Contacts:
Telex
Lawrence keusch
Deputy President, Relations with Investors and Strategy Development
Investor.relations@teleflex.com
610-948-2836